If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY.
Description
Monoclonal human IgG1 antibody against human PD-1. Pembrolizumab (Keytruda) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of patients with unresectable or metastatic melanoma. Pembrolizumab binds to the human cell surface receptor PD-1 (Programmed Cell Death Protein 1) and blocks its interaction with PD-L1, resulting in the activation of T-cell-mediated immune responses against tumor cells.